NCT06717295Recruiting
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 6000 (estimated)
- First submitted
- 28 Nov 2024
- Start date
- 20 Dec 2025
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- Javier Toledo
- Diseases
- Prostate cancer, Lung cancer, Pancreatic cancer, Colorectal cancer, Liver and biliary tract cancer, Glioblastoma, Ovarian cancer
- NCT number
- NCT06717295
What you commit to
- Study type: Observational
- Planned participants: 6000
- From 20 Dec 2025 to the primary completion date, 1 Aug 2027
- 4 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of anticoagulant or antiplatelet drugs within the past 2 weeks.
Other illness
- Presence of any active infectious diseases.
- Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.
- Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)
- Presence of another malignancy unless it has been in remission for at least 5 years.
- Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.
Other
- Currently pregnant.
Who the study is looking for
- Age: Adults aged 40 years or older.
- Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.
- Adults aged 40 years or older.
- Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)
- Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).
Criteria the registry did not label
- Phase 1 (Common Cancer Early Detection - CCANED)
Age in the registry: 40 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Various Cancer Centres Coordinator of this site? Confirm its status | Rosario | Argentina | Active, not recruiting |
| Babraham Research Institute Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Enrolling by invitation |
| Dysplasia Diagnostics Limited Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| NSIA- Lagos University Teaching Hospital Cancer Centre Coordinator of this site? Confirm its status | Lagos | Nigeria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.